BOSTON– Neutron Therapeutics, a targeted radiation therapy company developing a comprehensive solution for Boron Neutron Capture Therapy (BNCT), announced today that it has appointed Elizabeth Reczek, Ph.D., as its Chief Executive Officer and member of its Board of Directors.
Dr. Reczek brings to Neutron deep and varied experience in the leadership of life science companies. Previously, as CEO of SeqLL, Inc., a single-molecule DNA/RNA sequencing company, she led the company’s transition from technology development to its commercialization stage. Prior to SeqLL, Dr. Reczek was CEO of Excelimmune, Inc., a polyclonal antibody therapeutic company developing treatments for antibiotic-resistant infections. Additionally, she has served as an Entrepreneur in Residence at Partners Innovation, a Partner in Ravello Precision Partners, a biotech-focused hedge fund based in New York, and an advisor to a range of early-stage life science startup companies. Dr. Reczek obtained her B.A. in Biochemical Sciences from Harvard University and her Ph.D. in Cancer Biology from Massachusetts Institute of Technology. She joined Neutron Therapeutics in early 2020 to develop the Company’s strategy for novel boron carrier drugs, a critical component of Neutron’s complete solution for BNCT.
“Neutron Therapeutics has positioned itself as a clear leader in BNCT commercialization with its nuBeam® installations in Europe and Japan. I’m extremely excited to work with the Neutron team and with our many international collaborators to make BNCT therapy available for patients suffering from a wide range of devastating solid tumors,” said Reczek.
Theodore Smick, Neutron Therapeutics’ co-founder and former CEO, will remain on the Board as he assumes the role of Chief Technology Officer, leveraging 40 years of experience in the accelerator industry in leading the Company’s technology development efforts. He remarked, “I am thrilled to welcome Liz to Neutron Therapeutics and look forward to working with her to bring the company forward in this next phase of our growth.”
“Neutron Therapeutics has embarked on an ambitious strategy to advance the commercialization of a complete clinical solution for this powerful therapy to hospitals around the world,” added Company co-founder and Chairman of its Board of Directors, Bill Buckley. “Liz brings the precise mix of business acumen and scientific expertise we need to execute this strategy successfully and maintain our industry leading position. We are very excited to have her on board.”
